Crossject strengthens balance sheet as BARDA deal extended to $48m
Crossject, the French specialty pharmaceutical company behind the ZENEO needle-free autoinjector, has reported first-half 2026 results showing a markedly improved financial position following a €15 million capital increase completed in May. The Euronext-listed group said shareholders' equity returned to positive territory at €3.0 million, reversing a deficit of €4.9 million recorded at year-end 2025, while cash and cash equivalents more than doubled to €12.3 million.
The balance sheet repair came at a cost to headline revenues. Operating revenue fell 40% to €4.8 million in the six months to June 30, down from €8.0 million in the comparable period of 2025. The company attributed the decline almost entirely to timing: first-half 2025 had captured a validation campaign and a clinical study under Crossject's contract with the US Biomedical Advanced Research and Development Authority (BARDA), activities that pulled forward significant reimbursable expenditure. Without those one-off milestones, BARDA billing normalised to €2.5 million in the current period. Net loss widened to €8.6 million from €4.9 million a year earlier, reflecting the lower revenue base on a broadly stable cost structure.
Financial restructuring
The May capital raise issued 6.44 million new shares at €1.704 each, accompanied by stock subscription warrants. If all warrants are exercised, Crossject could receive a further €21.6 million in non-dilutive-equivalent proceeds. The company also converted €2.07 million of convertible bonds into equity during the half, helping to reduce gross financial debt from €22.4 million to €18.6 million. Adjusted net financial debt fell by more than half to €7.8 million. Chief financial officer Lionel Seltz, who joined the group in January 2026, said the priority is to "manage cash flow with the utmost rigour and to secure the company's financing, giving priority to non-dilutive resources, until ZEPIZURE generates its first commercial revenue."
BARDA extension and ZEPIZURE regulatory path
The most significant post-period development is Amendment 4 to the BARDA contract, which extends the performance period to June 2030 and adds $4.7 million in non-dilutive funding, bringing total committed BARDA support for ZEPIZURE to $48.0 million. The expanded scope includes a paediatric clinical trial and an additional validation campaign with extended stability studies, though Crossject noted neither is a prerequisite for filing an Emergency Use Authorisation application for the adult indication.
ZEPIZURE is an injectable diazepam formulation for epileptic seizures, designed to be administered via the ZENEO autoinjector without a needle. The French medicines regulator ANSM issued a new Good Manufacturing Practice compliance certificate following a site inspection during the period, and the company retains ISO 13485 certification across its French facilities. Crossject has invested €3.9 million in assets under construction as it prepares production capacity and its supply chain for first deliveries.
Market context and competitive landscape
The needle-free autoinjector market for emergency indications is relatively concentrated, with a small number of device and pharmaceutical companies pursuing both military and civilian first-responder applications. Uniject and Portal Instruments are among device-focused players, while established injectable emergency-medicine portfolios from larger pharmaceutical groups represent indirect competition. Crossject's differentiation rests on the ZENEO platform's suitability for untrained users in pre-hospital settings, a characteristic that BARDA's continued and expanded support implicitly endorses.
For investors, the near-term question is whether cash of €12.3 million, together with ongoing BARDA reimbursements and potential warrant exercises, is sufficient to sustain operations to first commercial revenue. The company has not disclosed an expected EUA filing date, in line with an agreed communications strategy with BARDA. Five research firms now cover the stock, following Portzamparc's initiation in February 2026, which should improve price discovery as regulatory milestones approach.